Fabry recap | SGMO Message Board Posts


Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  167993 of 168915  at  9/29/2022 10:23:32 PM  by

ZFP


 In response to msg 167991 by  rynotheknife
view thread

Re: Fabry recap

As well he should. As SM has said it will be hard for the FDA to agree to AA absent a comparison to the SOC. Down playing without eliminating is facing facts

You may want to go back to see what MacKay actually said. It wasn't that the pathway was closed, but that achieving accelerated approval was no longer possible given the way the AVRO trial was designed.

Perhaps compensating him 20% more than SM over the past 2 years could have been better spent on trial design.

Facts can be inconvenient at times.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
167995 Re: Fabry recap nocashonhand 0 9/30/2022 1:52:51 AM
167996 Re: Fabry recap rynotheknife 0 9/30/2022 4:11:35 AM




Financial Market Data provided by
.
Loading...